Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical bioequivalence. Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER.

Similar presentations


Presentation on theme: "Clinical bioequivalence. Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER."— Presentation transcript:

1 Clinical bioequivalence

2 Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER acknowledges that existing in vitro potency tests will be applicable to the new preparation. However, CBER requests that the manufacturer demonstrate compositional similarity by parallel line bioassay

3 Clinical bioequivalence

4

5 “At least 4 subjects are required per assay. One or more test extracts are to be compared against a reference in each subject. For evaluating compositional differences, subjects…selectively sensitive to specific allergens in the crude mix should be selected…[I]n order to enhance detection of compositional differences, subjects can be selected who differ widely (10-10,000 fold) in their allergen skin test sensitivity…to the test of reference extracts.”

6

7

8

9 Manufacturer proposal n Based on the 1993 protocol, the manufacturer proposes to enlist 4 to 6 study subjects of varying levels of sensitivity to fedweed pollen n If the slopes of the two preparations are not significantly different in these study subjects, the manufacturer will conclude that the two preparations are compositionally similar

10 Initial assumptions n Mean slope: 10 n Acceptable difference: 10% = 1 n SD slope: 1 n  = 0.05  = 0.2  = 0.2

11

12 To determine the number of subjects (n) required to detect a difference  with confidence  and power 1 -  with the two one-sided test approach, use the following:

13 For  = 0.05 and  = 0.2:

14

15 Conclusions n The failure to demonstrate a difference is not sufficient to demonstrate equivalence Given that, for the parallel line bioassay, , the number of study subjects required to demonstrate equivalence will usually exceed 4-6 Given that, for the parallel line bioassay, , the number of study subjects required to demonstrate equivalence will usually exceed 4-6

16 Advisory Committee discussion CBER requests that the Committee discuss CBER’s current approach to clinical bioequivalence studies as it applies to allergen extract studies.


Download ppt "Clinical bioequivalence. Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER."

Similar presentations


Ads by Google